Retroviruses and Novel Drugs

Biography

Biography: Maduike Ezeibe

Abstract

Small size  of viruses  allows them access to organs that are in-access-able to medicines (big molecules).  When patients  are  treated, immunity clears such infections but for infections that cause immune-deficiency, there would be nothing  to clear them. Affected organs become their “sanctuary” . Aluminum silicate and Magnesium silicate were reacted {Al₄(SiO₄)₃ + 3Mg₂SiO₄→2Al₂Mg₃(SiO₄)₃} for the medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®).  Molecules  of  MSAMS  are made of Nanoparticles  with positive and  negative electrically charged ends.  Ultra small size of MSAMS-Nanoparticles allows them access to all organs. They bond their  ends to opposite  charges, on viruses and  on infected  cells.  MSAMS  also provokes  lymphocytosis. Synergy between its antiviral  effects  and  the lymphocytosis terminates viral infections. HIV-infected persons were classified as: (i) HIV-positive patients (CD4 ≥500) and (ii) HIV/AIDS patients (CD4 <500). Each patient was treated, daily, with Antivirt® (50mg/kg) and  immunace extra-protection® (1 tablet). They were tested before the treatment and every month, for viral loads and CD4 counts. Mean CD4 counts  of the HIV-positive patients (663.60±45.43) was more (P=0.00) than that of the HIV/AIDS patients (330.00±32.01) but means of  their monthly  CD4 before they recovered (1461.78±339.84 and 1400.00±301.30) became approximately same (P=0.89). HIV antigens and antibodies regressed, completely, in HIV-positive patients  after  8.40±0.24 months while it took 10.00 ±0.00  months  before HIV/AIDS patients recovered (P=0.00 ). Symptoms were observed in HIV/AIDS patients but the HIV-positives remained apparently healthy. Conclusion is that  patients at both HIV-positive stage  and  HIV/AIDS stage can recover, if treated with  the Antivirt®-immune stimulants regimen.